Shayna E Thomas-Jardin1, Mohammed S Kanchwala2, Joan Jacob1, Sana Merchant1, Rachel K Meade1, Nagham M Gahnim1, Afshan F Nawas1, Chao Xing2,3,4, Nikki A Delk1. 1. Biological Sciences Department, The University of Texas at Dallas, Richardson, Texas. 2. McDermott Center of Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, Texas. 3. Department of Bioinformatics, The University of Texas Southwestern Medical Center, Dallas, Texas. 4. Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+ ) PCa cells into AR negative (AR- ) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. METHODS: LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. RESULTS: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR- PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. CONCLUSIONS: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR- PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.
BACKGROUND: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+ ) PCa cells into AR negative (AR- ) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. METHODS:LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. RESULTS: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR- PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. CONCLUSIONS: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR- PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.
Authors: Megan A Chang; Micaela Morgado; Curtis R Warren; Cimona V Hinton; Mary C Farach-Carson; Nikki A Delk Journal: Prostate Date: 2013-09-30 Impact factor: 4.104
Authors: Minjung J Kim; Robert D Cardiff; Nishita Desai; Whitney A Banach-Petrosky; Ramon Parsons; Michael M Shen; Cory Abate-Shen Journal: Proc Natl Acad Sci U S A Date: 2002-02-19 Impact factor: 11.205
Authors: Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert Journal: Int J Cancer Date: 2007-09-01 Impact factor: 7.396
Authors: Robert S Bayne; Shelby Puckett; Lindsey Ulkus Rodrigues; Scott D Cramer; Jingyun Lee; Cristina M Furdui; Jeff W Chou; Lance D Miller; David A Ornelles; Douglas S Lyles Journal: Mol Ther Oncolytics Date: 2020-05-20 Impact factor: 7.200
Authors: Andras Franko; Lucia Berti; Alke Guirguis; Jörg Hennenlotter; Robert Wagner; Marcus O Scharpf; Martin Hrabĕ de Angelis; Katharina Wißmiller; Heiko Lickert; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Hans-Ulrich Häring; Stefan Z Lutz; Martin Heni Journal: Genes (Basel) Date: 2020-10-07 Impact factor: 4.096
Authors: Haley C Dahl; Mohammed Kanchwala; Shayna E Thomas-Jardin; Amrit Sandhu; Preethi Kanumuri; Afshan F Nawas; Chao Xing; Chenchu Lin; Daniel E Frigo; Nikki A Delk Journal: PLoS One Date: 2020-12-16 Impact factor: 3.240